Delta-aminolevulinic acid dehydratase polymorphism and the relation between low level lead exposure and the Mini-Mental Status Examination in older men: The Normative Aging Study

Occupational and Environmental Medicine

Volumn 63, Issue 11, 2006, Pages 746-753

  Weuve, J ^a   Kelsey, K T ^a   Schwartz, J ^a,g   Bellinger, D ^b,c   Wright, R O ^a,b,g   Rajan, P ^a   Spiro III, A ^d,e   Sparrow, D ^d,e,f   Aro, A ^a,g   Hu, H ^a,g  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d DEPARTMENT OF VETERANS AFFAIRS   (United States)

^e BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^f BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; LEAD; PORPHOBILINOGEN SYNTHASE;

ADULT; AGED; AGING; ARTICLE; BONE LEVEL; COGNITION; ENZYME POLYMORPHISM; FLUORESCENCE; GENOTYPE; HUMAN; LEAD BLOOD LEVEL; MAJOR CLINICAL STUDY; MENTAL HEALTH; NEUROTOXICITY; PRIORITY JOURNAL; VETERAN;

ADULT; AGED; AGED, 80 AND OVER; COGNITION; COHORT STUDIES; ENVIRONMENTAL EXPOSURE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LEAD; LEAD POISONING, NERVOUS SYSTEM, ADULT; LONGITUDINAL STUDIES; MALE; MENTAL STATUS SCHEDULE; MIDDLE AGED; PATELLA; POLYMORPHISM, GENETIC; PORPHOBILINOGEN SYNTHASE; TIBIA;

EID: 33750602304     PISSN: 13510711     EISSN: None     Source Type: Journal    
DOI: 10.1136/oem.2006.027417     Document Type: Article

References (47)

1. Koller K, Brown T, Spurgeon A, et al. Recent developments in low-level lead exposure and intellectual impairment in children. Environ Health Perspect 2004;112:987-94.
2. Schwartz BS, Stewart WF. Different associations of blood lead, meso 2,3-dimercaptosuccinic acid (DMSA)-chelatable lead, and tibial lead levels with blood pressure in 543 former organolead manufacturing workers. Arch Environ Health 2000;55:85-92.
3. Fiedler N, Weisel C, Lynch R, et al. Cognitive effects of chronic exposure to lead and solvents. Am J Ind Med 2003;44:413-23.
4. Bleeker MW, Netea MG, Kullberg BJ, et al. The effects of dexamethasone and chlorpromazine on tumour necrosis factor-alpha, interleukin-1 beta, interleukin-1 receptor antagonist and interleukin-10 in human volunteers. Immunology 1997;91:548-52.
5. Balbus-Kornfeld JM, Stewart W, Bolla KI, et al. Cumulative exposure to inorganic lead and neurobehavioural test performance in adults: an epidemiological review. Occup Environ Med 1995;52:2-12.
6. Hebert LE, Scherr PA, Bienias JL, et al. Alzheimer disease in the US population: prevalence estimates using the 2000 Census. Arch Neurol 2003;60:1119-22.
7. Weisskopf MG, Wright RO, Schwartz J, et al. Cumulative lead exposure and prospective change in cognition among elderly men: the VA Normative Aging Study. Am J Epidemiol 2004;160:1184-93.
8. Schwartz BS, Lee BK, Bandeen-Roche K, et al. Occupational lead exposure and longitudinal decline in neurobehavioral test scores. Epidemiology 2005;16:106-13.
9. Kelada SN, Shelton E, Kaufmann RB, et al. Delta-aminolevulinic acid dehydratase genotype and lead toxicity: a HuGE review. Am J Epidemiol 2001;154:1-13.
10. Wetmur JG, Kaya AH, Plewinska M, et al. Molecular characterization of the human delta-aminolevulinate dehydratase 2 (ALAD2) allele: implications for molecular screening of individuals for genetic susceptibility to lead poisoning. Am J Hum Genet 1991;49:757-63.
11. Wetmur JG. Influence of the common human delta-aminolevulinate dehydratase polymorphism on lead body burden. Environ Health Perspect 1994;102(Suppl 3):215-9.
12. Onalaja AO, Claudio L. Genetic susceptibility to lead poisoning. Environ Health Perspect 2000;108(Suppl 1):23-8.
13. Minnema DJ, Michaelson IA. Differential effects of inorganic lead and delta-aminolevulinic acid in vitro on synaptosomal gamma-aminobutyric acid release. Toxicol Appl Pharmacol 1986;86:437-47.
14. Chia SE, Yap E, Chia KS. Delta-aminolevulinic acid dehydratase (ALAD) polymorphism and susceptibility of workers exposed to inorganic lead and its effects on neurobehavioral functions. Neurotoxicology 2004;25:1041-7.
15. Sakai T, Morita Y, Araki T, et al. Relationship between delta-aminolevulinic acid dehydratase genotypes and heme precursors in lead workers. Am J Ind Med 2000;38:355-60.
16. Sithisarankul P, Schwartz BS, Lee BK, et al. Aminolevulinic acid dehydratase genotype mediates plasma levels of the neurotoxin, 5-aminolevulinic acid, in lead-exposed workers. Am J Ind Med 1997;32:15-20.
17. Wright RO, Tsaih SW, Schwartz J, et al. Lead exposure biomarkers and minimental status exam scores in older men. Epidemiology 2003;14:713-8.
18. Bell B, Rose CL, Damon A. The Veterans Administration longitudinal study of healthy aging. Gerontologist 1966;6:179-84.
19. Hu H, Rabinowitz M, Smith D. Bone lead as a biological marker in epidemiologic studies of chronic toxicity: conceptual paradigms. Environ Health Perspect 1998;106:1-8.
20. Folstein MF, Folstein SE, McHugh PR. Mini-Mental State: A practical method for grading the slate of patients for the clinician. J Psychiatr Res 1975;12:189-98.
21. Agency for Toxic Substances and Disease Registry. Draft toxicological profile for lead. Altanta, GA: Public Health Service, US Department of Health and Human Services, 2005.
22. Hu H, Tosteson T, Aufderheide AC, et al. Distribution of lead in human bone: I. Atomic absorption measurements. Basic Life Sci 1990;55:267-74.
23. Burger DE, Milder FL, Morsillo PR, et al. Automated bone lead analysis by K-x-ray fluorescence for the clinical environment. Basic Life Sci 1990;55:287-92.
24. Kim R, Landrigan C, Mossmann P, et al. Age and secular trends in bone lead levels in middle-aged and elderly men: three-year longitudinal follow-up in the Normative Aging Study. Am J Epidemiol 1997;146:586-91.
25. Schwartz BS, Lee BK, Stewart W, et al. Associations of delta-aminolevulinic acid dehydratase genotype with plant, exposure duration, and blood lead and zinc protoporphyrin levels in Korean lead workers. Am J Epidemiol 1995;142:738-45.
26. Tombaugh TN, McIntyre NJ. The mini-mental state examination: a comprehensive review. J Am Geriatr Soc 1992;40:922-35.
27. Hastie TJ, Tibshirani RJ. Generalized additive models. New York, NY: Chapman & Hall, 1990.
28. Wood SN. Low rank scale invariant tensor product smooths for Generalized Additive Mixed Models. Technical report of the statistics department, University of Glasgow, 2004.
29. Payton ME, Greenstone MH, Schenker N. Overlapping confidence intervals or standard error intervals: What do they mean in terms of statistical significance? J Insect Sci 2003;3:34-9.
30. Bergdahl IA, Gerhardsson L, Schutz A, et al. Delta-aminolevulinic acid dehydratase polymorphism: influence on lead levels and kidney function in humans. Arch Environ Health 1997;52:91-6.
31. Stuss DT, Meiran N, Guzman DA, et al. Do long tests yield a more accurate diagnosis of dementia than short tests? A comparison of 5 neuropsychological tests. Arch Neurol 1996;53:1033-9.
32. Bellinger D, Hu M, Titlebaum L, et al. Attentional correlates of dentin and bone lead levels in adolescents. Arch Environ Health 1994;49:98-105.
33. Louis ED, Applegate L, Graziano JH, et al. Interaction between blood lead concentration and delta-amino-levulinic acid dehydratase gene polymorphisms increases the odds of essential tremor. Mov Disord 2005;20:1170-7.
34. Wu MT, Kelsey K, Schwartz J, et al. A delta-aminolevulinic acid dehydratase (ALAD) polymorphism may modify the relationship of low-level lead exposure to uricemia and renal function: the normative aging study. Environ Health Perspect 2003;111:335-41.
35. Lee BK, Lee GS, Stewart WF, et al. Associations of blood pressure and hypertension with lead dose measures and polymorphisms in the vitamin D receptor and delta-aminolevulinic acid dehydratase genes. Environ Health Perspect 2001;109:383-9.
36. Alexander BH, Checkoway H, Costa-Mallen P, et al. Interaction of blood lead and delta-aminolevulinic acid dehydratase genotype on markers of heme synthesis and sperm production in lead smelter workers. Environ Health Perspect 1998;106:213-16.
37. Agency for Toxic Substances and Disease Registry. Toxicological profile for lead. Altanta, GA: Public Health Service, US Department of Health and Human Services, 1999.
38. Claudio L, Lee T, Wolff MS, et al. A murine model of genetic susceptibility to lead bioaccumulation. Fundam Appl Toxicol 1997;35:84-90.
39. Hu H, Wu MT, Cheng Y, et al. The delta-aminolevulinic acid dehydratase (ALAD) polymorphism and bone and blood lead levels in community-exposed men: the Normative Aging Study. Environ Health Perspect 2001;109:827-32.
40. Shen XM, Wu SH, Van CH, et al. Delta-aminolevulinate dehydratase polymorphism and blood lead levels in Chinese children. Environ Res 2001;85:185-90.
41. Kim HS, Lee SS, Lee GS, et al. The protective effect of delta-aminolevulinic acid dehydratase 1 -2 and 2-2 isozymes against blood lead with higher hematologic parameters. Environ Health Perspect 2004;112:538-41.
42. Bergdahl IA, Grubb A, Schulz A, et al. Lead binding to delta-aminolevulinic acid dehydratase (ALAD) in human erythrocytes. Pharmacol Toxicol 1997;81:153-8.
43. Suzen HS, Duydu Y, Aydin A, et al. Influence of the delta-aminolevulinic acid dehydratase (ALAD) polymorphism on biomarkers of lead exposure in Turkish storage battery manufacturing workers. Am J Ind Med 2003;43:165-71.
44. Smith CM, Wang X, Hu H, et al. A polymorphism in the delta-aminolevulinic acid dehydratase gene may modify the pharmacokinetics and toxicity of lead. Environ Health Perspect 1995;103:248-53.
45. Schwartz BS, Lee BK, Stewart W, et al. delta-Aminolevulinic acid dehydratase genotype modifies four hour urinary lead excretion after oral administration of dimercaptosuccinic acid. Occup Environ Med 1997;54:241-6.
46. Jaffe EK, Martins J, Li J, et al. The molecular mechanism of lead inhibition of human porphobilinogen synthase. J Biol Chem 2001;276:1531-7.
47. Montenegro MF, Barbosa F Jr, Sandrim VC, et al. A polymorphism in the delta-aminolevulinic acid dehydratase gene modifies plasma/whole blood lead ratio. Arch Toxicol 2005;80:394-8.